Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
HumuLIN R
(United States) [Available] ,Myxredlin
(United States) [Available]Synonyms :
Class :
Antidiabetics, Insulins
Dosage forms & Strengths:Â
Injectable solution:Â
100 units/mlÂ
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
choline magnesium trisalicylate
May increase the hypoglycemic effect of each other when combined
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
garcinia along with other antidiabetic drugs will lead to abrupt decease in blood sugar levels
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the hypoglycemic effect
may decrease the therapeutic effect of corticosteroids
ciprofloxacin inhaled (Pending FDA approval)Â
may enhance the hypoglycemic effect of Quinolones
may diminish the therapeutic effect of hyperglycaemia associated agents
spironolactone and hydrochlorothiazide
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
choline magnesium trisalicylate
salicylates may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
choline magnesium trisalicylate
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
relugolix/​estradiol/​norethindrone
androgens increase the effect of hypoglycemia in these agents
relugolix/estradiol/norethindrone
androgens increase the effect of hypoglycemia in these agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
blood sugar levels can be seen additionally reduced when antidiabetic drugs are used in combination with anti glaucoma agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
antiviral Agents may enhance the hypoglycemic effect of anti-diabetic Agents
antiviral Agents may enhance the hypoglycemic effect of anti-diabetic Agents
antiviral Agents may enhance the hypoglycemic effect of anti-diabetic Agents
antiviral Agents may enhance the hypoglycemic effect of anti-diabetic Agents
antiviral Agents may enhance the hypoglycemic effect of anti-diabetic Agents
May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may diminish the therapeutic effect of antidiabetic Agents
may diminish the therapeutic effect of antidiabetic Agents
may diminish the therapeutic effect of antidiabetic Agents
may diminish the therapeutic effect of antidiabetic Agents
may diminish the anticoagulant effect of vitamin K antagonists
may diminish the anticoagulant effect of vitamin K antagonists
may diminish the anticoagulant effect of vitamin K antagonists
may diminish the anticoagulant effect of vitamin K antagonists
may diminish the anticoagulant effect of vitamin K antagonists
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may decrease the therapeutic effect
choline magnesium trisalicylate
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
it increases the effect of hypoglycemia of antidiabetic agents
it increases the effect of hypoglycemia of antidiabetic agents
it decreases the efficacy of antidiabetic agents
may decrease the therapeutic effect of hyperglycemia agents
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect of androgens
may decrease the therapeutic effect
may diminish the therapeutic effect of corticosteroids
may increase the hypoglycemic effect of quinolones
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycaemic effect of beta blockers
hydrochlorothiazide/aliskirenÂ
may diminish the therapeutic effect of thiazide and thiazide like diuretics
lisinopril/hydrochlorothiazideÂ
may enhance the serum concentration of thiazide and thiazide like diuretics
methyldopa/hydrochlorothiazideÂ
may diminish the therapeutic effect of thiazide and thiazide like diuretics
may increase the hypoglycemic effect of direct-acting viral agents
may increase the hypoglycemic effect of direct-acting antiviral agents
may enhance the hypoglycemic effect of beta blockers
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the hypoglycemic effect of salicylates
may increase the hypoglycemic effect of hypoglycemia-associated agents
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
relugolix/​estradiol/​norethindrone
may enhance the hypoglycemic effect
relugolix/estradiol/norethindrone
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect of Hyperglycemia-Associated Agents
may have an increased hypoglycemic effect when combined with antidiabetic agents
may have an increased hypoglycemic effect when combined with antidiabetic agents
may have an increased hypoglycemic effect when combined with antidiabetic agents
estrogens esterified/methyltestosterone            Â
may increase the hypoglycemic effect of androgens
drospirenone/ethinyl estradiol/levomefolateÂ
may decrease the therapeutic effect of Hyperglycemia-Associated Agents
may decrease the therapeutic effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may enhance the hypoglycemic effect of each other when combined
may decrease the therapeutic effect of Hyperglycemia-Associated Agents
cyproterone and ethinyl estradiolÂ
may decrease the therapeutic effect of Hyperglycemia-Associated Agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with antidiabetic agents
may have an increased hypoglycemic effect when combined with antidiabetic agents
relugolix/estradiol/norethindrone
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
etilefrine: they may decrease the therapeutic effect of antidiabetic agents
may have an increased hypoglycemic effect when combined with antidiabetic agents
may have an increased hypoglycemic effect when combined with antidiabetic agents
Frequency undefined:Â
HypoglycemiaÂ
HypokalemiaÂ
Peripheral edemaÂ
Weight gainÂ
ImmunogenicityÂ
Hypersensitivity reactionsÂ
Regular insulin is contraindicated in patients hypersensitive to it or other components in the formulation. It is also contraindicated in patients with episodes of hypoglycemia.Â
Pregnancy consideration:Â Â
It is not secure to administer regular insulin during pregnancy.Â
Breastfeeding warnings:Â Â
No data about the excretion of regular insulin in human breast milk is available. Avoid using in lactating women.Â
Pregnancy category:Â
Â
Patient information leafletÂ
Generic Name: regular insulinÂ
Pronounced: reg-yuh-luh in-su-lin Â
Why do we use regular insulin?Â
Regular insulin treats type 1, type 2 diabetes mellitus, hyperkalemia, and diabetic ketoacidosis.Â